# GAGE12E

## Overview
GAGE12E is a gene that encodes the G antigen 12E protein, which is part of the GAGE family of cancer-testis antigens. These proteins are typically expressed in a variety of cancers and are known for their restricted expression in normal tissues, primarily in the testis. The G antigen 12E protein is implicated in oncogenic processes, including tumor progression and metastasis, by influencing pathways such as the epithelial-to-mesenchymal transition (EMT) and modulating immune responses. Its expression is notably upregulated in certain cancers, such as hepatocellular carcinoma and multiple myeloma, where it serves as a potential biomarker for prognosis and a target for therapeutic intervention (Nin2023Biology; Cheng2021Growth; Moreaux2010A).

## Clinical Significance
GAGE12E, a member of the GAGE family of cancer-testis antigens, is implicated in various cancers due to its altered expression levels. In hepatocellular carcinoma (HCC), GAGE12E expression is upregulated by Growth Differentiation Factor 1 (GDF1), which enhances tumor plasticity and may increase sensitivity to immune-based therapies. This upregulation is linked to the suppression of the epigenetic regulator LSD1, suggesting a potential therapeutic window for using LSD1 inhibitors in HCC treatment (Cheng2021Growth).

In multiple myeloma, GAGE12 is overexpressed in certain patient groups, correlating with poor prognostic outcomes. This overexpression is associated with shorter event-free survival and overall survival, indicating its potential role as a prognostic marker (Moreaux2010A).

GAGE12E is also involved in the metastatic potential of gastric cancer cells. Its expression correlates with the activation of pathways that promote cell motility and invasiveness, such as the epithelial-to-mesenchymal transition (EMT) process. This suggests that GAGE12E may contribute to cancer metastasis and could be a target for therapeutic interventions aimed at reducing metastatic spread (Nin2023Biology).


## References


[1. (Nin2023Biology) Dawn Sijin Nin and Lih-Wen Deng. Biology of cancer-testis antigens and their therapeutic implications in cancer. Cells, 12(6):926, March 2023. URL: http://dx.doi.org/10.3390/cells12060926, doi:10.3390/cells12060926. This article has 18 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cells12060926)

[2. (Cheng2021Growth) Wei Cheng, Hao-Long Li, Shao-Yan Xi, Xiao-Feng Zhang, Yun Zhu, Le Xing, Yan-Xuan Mo, Mei-Mei Li, Fan-En Kong, Wen-Jie Zhu, Xiao-Gang Chen, Hui-Qing Cui, Zhi-Ming Cao, Yuan-Feng Gong, Yun-Qiang Tang, Yan Zhang, Xin-Yuan Guan, Ning-Fang Ma, and Ming Liu. Growth differentiation factor 1-induced tumour plasticity provides a therapeutic window for immunotherapy in hepatocellular carcinoma. Nature Communications, December 2021. URL: http://dx.doi.org/10.1038/s41467-021-27525-9, doi:10.1038/s41467-021-27525-9. This article has 20 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-021-27525-9)

[3. (Moreaux2010A) J. Moreaux, B. Klein, R. Bataille, G. Descamps, S. Maiga, D. Hose, H. Goldschmidt, A. Jauch, T. Reme, M. Jourdan, M. Amiot, and C. Pellat-Deceunynck. A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica, 96(4):574â€“582, December 2010. URL: http://dx.doi.org/10.3324/haematol.2010.033456, doi:10.3324/haematol.2010.033456. This article has 127 citations.](https://doi.org/10.3324/haematol.2010.033456)